Will 2016 Be Novartis' Worst Year Yet?
WIth its top seller facing increased generic competition, this could be a very bad year, indeed.
Why Radius Health Inc. Dropped 45% in January
Good news from the clinical-stage osteoporosis specialist couldn't overcome January's biotech beat down.
Pre-Market Most Active for Feb 8, 2016 : CBX, NVS, TVIX, AZN, NOK, MT, BCRX, QQQ, FB, XIV, BAC, APO
Pre-Market Most Active for Feb 8, 2016 : CBX, NVS, TVIX, AZN, NOK, MT, BCRX, QQQ, FB, XIV, BAC, APOL
3 Potential Blockbusters Moving the Needle for Big Pharma in 2016
These pharmas have some recently approved drugs that could singlehandedly boost total sales this year.
Biogen Inc. Takes Aim at Johnson & Johnson
Biogen's Samsung Bioepis has Remicade in its crosshairs.
Why Ophthotech Corporation Shares Tumbled 31% in January
The launch of trials in dry age-related macular degeneration failed to spark shares last month.